REATA PHARMACEUTICALS INC-A (RETA)
US75615P1030 - Common Stock
RETA gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 198 industry peers in the Pharmaceuticals industry. While RETA seems to be doing ok healthwise, there are quite some concerns on its profitability. RETA is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
RETA had negative earnings in the past year.
RETA had a negative operating cash flow in the past year.
RETA had negative earnings in each of the past 5 years.
RETA had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of RETA (-17.43%) is better than 66.82% of its industry peers.
RETA's Return On Equity of -100.38% is on the low side compared to the rest of the industry. RETA is outperformed by 62.56% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -17.43% | ||
| ROE | -100.38% | ||
| ROIC | N/A |
ROA(3y)-43.32%
ROA(5y)-39.17%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
RETA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
RETA does not have a ROIC to compare to the WACC, probably because it is not profitable.
RETA has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, RETA has more shares outstanding
There is no outstanding debt for RETA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
RETA has an Altman-Z score of 2.68. This is not the best score and indicates that RETA is in the grey zone with still only limited risk for bankruptcy at the moment.
RETA has a better Altman-Z score (2.68) than 73.46% of its industry peers.
RETA has a Debt/Equity ratio of 0.84. This is a neutral value indicating RETA is somewhat dependend on debt financing.
The Debt to Equity ratio of RETA (0.84) is worse than 69.19% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.84 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 2.68 |
ROIC/WACCN/A
WACC9.36%
2.3 Liquidity
A Current Ratio of 3.21 indicates that RETA has no problem at all paying its short term obligations.
RETA's Current ratio of 3.21 is in line compared to the rest of the industry. RETA outperforms 46.45% of its industry peers.
A Quick Ratio of 3.19 indicates that RETA has no problem at all paying its short term obligations.
RETA's Quick ratio of 3.19 is in line compared to the rest of the industry. RETA outperforms 51.18% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.21 | ||
| Quick Ratio | 3.19 |
3. Growth
3.1 Past
RETA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 64.40%, which is quite impressive.
Looking at the last year, RETA shows a very strong growth in Revenue. The Revenue has grown by 134.81%.
Measured over the past years, RETA shows a very negative growth in Revenue. The Revenue has been decreasing by -45.95% on average per year.
EPS 1Y (TTM)64.4%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q330.2%
Revenue 1Y (TTM)134.81%
Revenue growth 3Y-56.28%
Revenue growth 5Y-45.95%
Revenue growth Q2Q2885.04%
3.2 Future
The Earnings Per Share is expected to grow by 24.33% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 250.01% on average over the next years. This is a very strong growth
EPS Next Y20.24%
EPS Next 2Y21.45%
EPS Next 3Y33.26%
EPS Next 5Y24.33%
Revenue Next Year3350.89%
Revenue Next 2Y1128.24%
Revenue Next 3Y529.02%
Revenue Next 5Y250.01%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
RETA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year RETA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as RETA's earnings are expected to grow with 33.26% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y21.45%
EPS Next 3Y33.26%
5. Dividend
5.1 Amount
RETA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
REATA PHARMACEUTICALS INC-A
NASDAQ:RETA (9/25/2023, 7:12:09 PM)
After market: 172.4 +0.04 (+0.02%)172.36
+0.04 (+0.02%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap5.79B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -17.43% | ||
| ROE | -100.38% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.05
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.84 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.21 | ||
| Quick Ratio | 3.19 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)64.4%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y20.24%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)134.81%
Revenue growth 3Y-56.28%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y